US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Amplia Therapeutics Ltd (OP:INNMF)

0.0540 UNCHANGED
Delayed Quote Updated: 11:16 AM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amplia Therapeutics Ltd

News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced
Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live from investors. 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
From Amplia Therapeutics Limited
Via GlobeNewswire
News headline image
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
From Amplia Therapeutics Limited
Via GlobeNewswire
News headline image
Amplia Announces Publication of New FAK Inhibitor Patent Application
From Amplia Therapeutics Limited
Via GlobeNewswire
News headline image
Amplia Announces Appointment of Brett Carter to Board
From Amplia Therapeutics Limited
Via GlobeNewswire
News headline image
Amplia Announces Changes to Board’s Leadership Roles
From Amplia Therapeutics Limited
Via GlobeNewswire
News headline image
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
From Amplia Therapeutics Limited
Via GlobeNewswire
News headline image
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Accent Trial Mature Data Presented at International Conference
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at... 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
NARMAFOTINIB Large-Scale Manufactre Complete
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Additional Confirmed Response Reported as Part of Amplia Investor Presentation
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences; Amplia Therapeutics
Via GlobeNewswire
News headline image
Key Narmafotinib Patent Granted in the U.S.
From Amplia Therapuetics Limited
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for September 18th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire